Back to Newsroom

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., July 05, 2017 (GLOBE NEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that on July 3, 2017, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 200,000 shares of Curis common stock to two new employees, with a grant date of July 3, 2017 (the “Q3 2017 Inducement Grants”).